Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism - PubMed
12 hours ago
- #anticoagulants
- #venous thromboembolism
- #bleeding risk
- Apixaban and rivaroxaban are commonly used oral anticoagulants for treating acute venous thromboembolism (VTE).
- A randomized trial compared bleeding risks between apixaban and rivaroxaban in 2760 patients with acute VTE over 3 months.
- Apixaban showed a significantly lower risk of clinically relevant bleeding (3.3%) compared to rivaroxaban (7.1%).
- Death rates were very low in both groups (0.1% for apixaban vs. 0.3% for rivaroxaban).
- Serious non-bleeding adverse events were similar between the two groups (2.7% for apixaban vs. 2.2% for rivaroxaban).
- The study concluded that apixaban is safer regarding bleeding risk than rivaroxaban for acute VTE treatment.